eFFECTOR Therapeutics Reports Positive Data Updates from

Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in...

Related Keywords

Chicago ,Illinois ,United States ,American ,Doug Warner ,Sarat Chandarlapaty ,Ezra Rosen ,Mike Tattory ,Christopherm Calabrese ,Steve Worland ,Kevin Gardner ,Effector Therapeutics Inc ,Pfizer ,Exchange Commission ,American Society Of Clinical Oncology ,Lifesci Communications ,Nasdaq ,Memorial Sloan Kettering Cancer Center ,American Society ,Clinical Oncology ,Annual Meeting ,Investor Event ,Metastatic Breast ,Private Securities Litigation Reform Act ,Nasdaq Eftr ,Effector Therapeutics ,Nc ,